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Using a quantitative quadruple 
immunofluorescent assay to 
diagnose isolated mitochondrial 
Complex I deficiency
Syeda T. Ahmed1, Charlotte L. Alston1,2, Sila Hopton1,2, Langping He1,2, Iain P. Hargreaves3,4, 
Gavin Falkous1,2, Monika Oláhová1, Robert McFarland1, Doug M. Turnbull1, Mariana C. 
Rocha1,5 & Robert W. Taylor1,2
Isolated Complex I (CI) deficiency is the most commonly observed mitochondrial respiratory chain 
biochemical defect, affecting the largest OXPHOS component. CI is genetically heterogeneous; 
pathogenic variants affect one of 38 nuclear-encoded subunits, 7 mitochondrial DNA (mtDNA)-encoded 
subunits or 14 known CI assembly factors. The laboratory diagnosis relies on the spectrophotometric 
assay of enzyme activity in mitochondrially-enriched tissue homogenates, requiring at least 50 mg 
skeletal muscle, as there is no reliable histochemical method for assessing CI activity directly in tissue 
cryosections. We have assessed a validated quadruple immunofluorescent OXPHOS (IHC) assay to 
detect CI deficiency in the diagnostic setting, using 10 µm transverse muscle sections from 25 patients 
with genetically-proven pathogenic CI variants. We observed loss of NDUFB8 immunoreactivity in all 
patients with mutations affecting nuclear-encoding structural subunits and assembly factors, whilst 
only 3 of the 10 patients with mutations affecting mtDNA-encoded structural subunits showed loss of 
NDUFB8, confirmed by BN-PAGE analysis of CI assembly and IHC using an alternative, commercially-
available CI (NDUFS3) antibody. The IHC assay has clear diagnostic potential to identify patients with 
a CI defect of Mendelian origins, whilst highlighting the necessity of complete mitochondrial genome 
sequencing in the diagnostic work-up of patients with suspected mitochondrial disease.
Mitochondrial diseases are a group of clinically heterogeneous disorders caused by dysfunction of the oxidative 
phosphorylation (OXPHOS) system. Accounting for approximately 30% of all cases, isolated Complex I (CI) defi-
ciency is the most frequently observed biochemical manifestation of an OXPHOS defect in patients, particularly 
within a paediatric setting1. With a relative molecular mass of 1MDa, mitochondrial CI (NADH: ubiquinone 
oxidoreductase) is the largest complex of the respiratory chain, oxidising NADH to NAD+ and playing a central 
role in both electron transfer and cellular energy (ATP) production. The complex is L-shaped in structure, con-
sisting of 2 fragments; a hydrophilic peripheral arm, which extends into the matrix of the mitochondria and a 
hydrophobic arm which is embedded into the inner mitochondrial membrane. The complex is comprised of 45 
subunits, 7 of which are encoded by the mitochondrial DNA (mtDNA) and the remaining 38 subunits encoded by 
the nuclear DNA (nDNA)2. This structure can be further divided into 3 functional modules: within the peripheral 
arm the N module (which binds and oxidizes NADH, providing electrons to the Fe-S clusters) and the Q module 
(where ubiquinone is reduced to ubiquinol) whilst the membrane arm contains the third module known as the P 
module which catalyses proton transfer3–8.
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The assembly of CI is a multistep process; recent studies propose a modular assembly model, in which five 
assembly intermediates - termed Q/Pp-a, Pp-b, PD-a, PD-b and N - form separately before assembling into 
higher molecular mass intermediates to subsequently form the completed holoenzyme5. Despite differences in 
the nomenclature of assembly intermediates, all proposed models described in the recent literature follow the 
same sequence of steps9–12. Briefly, the first step involves formation of the Q module, followed by the addition of 
the mitochondrial encoded ND1 core subunit (early stage of assembly). Next, the membrane arm is assembled, 
starting with the insertion of ND2, ND3, ND6, ND4L (PP-b module), ND4 (PD-a) and ND5 (PD-b) (early-mid 
stage assembly and mid-late stage assembly). The membrane arm comes together with the Q module (Q-P mod-
ule) prior to the addition of the pre-assembled N module and remaining subunits (last stage of assembly)5,9,13.
To date, pathogenic variants have been reported in all 7 mtDNA core structural subunits (ND1–6 and ND4L), 
21 of the nuclear-encoded subunits and 10 of the known CI assembly factors (reviewed in refs14,15). Further to 
this genetic heterogeneity, CI deficiency also exhibits considerable clinical heterogeneity with the spectrum rang-
ing from severe presentations including Leigh Syndrome (LS) and fatal infantile mitochondrial disease in early 
childhood through to Leber Hereditary Optic Neuropathy (LHON) and exercise-induced muscle weakness which 
develop during young adult life.
The diagnosis of mitochondrial disease often uses a multidisciplinary approach including the histopatholog-
ical and biochemical assessment of tissue biopsy samples, usually skeletal muscle, as well as molecular genetic 
testing. Current histochemical methods to investigate mitochondrial disease are available for some OXPHOS 
components (e.g. the sequential assessment of cytochrome c oxidase (Complex IV, COX) and succinate dehy-
drogenase (Complex II, SDH)) but not all; no reliable histochemical assay is available to assess CI activity. Whilst 
validated biochemical assays can determine the activity of individual respiratory chain enzyme complexes, for 
example, CI by the spectrometric assay of rotenone-sensitive NADH oxidation, consensus diagnostic protocols 
are not widely adopted. Furthermore, most diagnostic laboratories request at least 50 mg of muscle tissue to reli-
ably measure enzyme activities, which represents a considerable proportion of the total amount of patient mate-
rial available, particularly in children. Additionally, the biochemical assay is known to only measure the redox 
activity of the peripheral arm of CI (containing the N-module and Q- module). Therefore, patients with muta-
tions residing in the membrane arm (P-module) - where only the proton pumping ability is affected rather than 
electron transport - may show a ‘normal’ enzyme profile following biochemical assessment despite an underlying 
CI defect, although this may reflect the level of mtDNA heteroplasmy in muscle tissue8. A confirmed diagnosis 
of isolated CI deficiency can facilitate appropriate molecular genetic testing to elucidate the underlying genetic 
cause, with screening of the mitochondrial genome preceding high throughput analysis of Mendelian candidates 
either by targeted gene panels, whole exome sequencing (WES) or whole genome sequencing (WGS)16.
Given the vast clinical and genetic heterogeneity associated with CI deficiency, accurate diagnosis is essen-
tial. A recently developed quadruple immunofluorescent assay to assess mitochondrial respiratory chain defects 
through the immunodetection of NDUFB8 (a CI subunit), COX-1 (a Complex IV subunit), porin (a mitochon-
drial mass marker) and laminin (a myofibre membrane marker) has been shown to provide an objective and reli-
able quantitative method for the assessment of CI and CIV protein abundance relative to the mitochondrial mass 
in individual muscle fibres within a single transversely-orientated, 10 µm muscle section17. We have extended this 
original study to assess CI status in skeletal muscle biopsies from 25 patients with proven pathogenic variants in 
proteins leading to a biochemical defect of isolated CI activity, including nuclear-encoded CI structural subunits, 
CI assembly factors, or one of the 7 mtDNA-encoded CI structural subunits. We demonstrate that the IHC assay 
has clear diagnostic potential, particularly for patients with Mendelian-inherited defects and propose that the 
IHC assay should form part of the multidisciplinary approach for the diagnostic investigation of patients with 
suspected CI deficiency.
Results
Mitochondrial Respiratory Chain (MRC) profiles. We assessed 25 skeletal muscle biopsies taken from 
patients with genetically-confirmed pathogenic variants either shown or predicted to cause isolated CI deficiency 
to validate a recently-developed immunofluorescence assay (IHC) within a diagnostic setting. The clinical, bio-
chemical and molecular genetic characteristics of this patient cohort are shown in Table 1. The IHC assay, detect-
ing CI subunit NDUFB8, CIV subunit COX-1 and porin (a marker of mitochondrial mass), was performed in 
all muscle sections (Supplementary Figs S1, S2 and S3), and fibres were classified according to Z scores – where 
any fibres with a Z score under -3SD were classified as deficient. The IHC results (NDUFB8 immunoreactivity), 
presented as a percentage of fibres deficient in CI – calculated by totalling the percentage of fibres classified as 
negative, intermediate negative and intermediate positive fibres (Table 2) - were subsequently correlated with the 
diagnostic biochemical findings, presented as residual CI activity (Table 1).
Group 1: Nuclear-encoded CI structural subunits. All eight patients who have pathogenic variants in 
nuclear-encoded CI structural core or accessory subunits (Group 1) showed varying levels of decreased NDUFB8 
immunoreactivity (representing a decrease in NDUFB8 protein abundance) when compared to control mus-
cle (Supplementary Fig. S1). Further analysis revealed that the proportion of CI-immunodeficient fibres ranged 
between 39% and 99% across this group of patients. The mitochondrial respiratory chain profiles (Fig. 1), showing 
the NDUFB8 and COX-1 protein abundance in conjunction with mitochondrial mass in individual fibres, also 
illustrates this as most fibres analysed were outside of the normal range for NDUFB8 (Z-score from -3SD to 3 SD) 
– causing a shift in their distribution on the plot to the left - despite the normal levels of COX-1 (subunit of com-
plex IV) in virtually all fibres assessed (n = 131–13422 fibres analysed; dependent on the size of muscle section). 
These findings were in agreement with the respiratory chain biochemical findings, where a decrease in residual 
CI activity was observed (Table 1).
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Patient Gender Adult/Paediatric Clinical Presentation Gene Genetic Defect
Residual Complex 
I activity
Mutation 
Load
Nuclear-encoded Complex I structural subunits
P1a F Paediatric
IUGR and oligohydramnios, 
FTT, mild hypertrophic 
cardiomyopathy
NDUFB3 Homozygous c.64 T > C, p.(Trp22Arg) 33% n.a.
P2b F Paediatric
IUGR. Acute life-threatening 
event, age 20 days, required 
intubation. Hypertrophic 
cardiomyopathy
NDUFB3 Homozygous c.64 T > C, p.(Trp22Arg) 32% n.a.
P3c F Paediatric
Oligohydramnios. IUGR. 
Poor feeding at birth. MRI 
brain and echocardiogram 
normal. Age-appropriate 
skills. Family history of 
previous neonatal death
NDUFB3 Homozygous c.64 T > C, p.(Trp22Arg) 35% n.a.
P4 F Paediatric Leigh syndrome NDUFS4
Compound heterozygous c.99-
1 G > A + c.416_417delinsC, 
p.(Glu139Alafs*50)
39% n.a.
P5 F Paediatric
Consanguineous, first cousin 
parents; Leigh-like syndrome; 
elevated lactates
NDUFS4 Homozygous exon 3 and 4 deletion 37% n.a.
P6 M Paediatric Infantile-onset mitochondrial disease; marked lactic acidosis NDUFS6
Homozygous c.316_319delGAAA, 
p.(Glu106Glnfs*41) 5% n.a.
P7 F Paediatric Leigh syndrome NDUFS2 Homozygous c.998 G > A, p.(Arg333Gln) 42% n.a.
P8 F Paediatric Leigh-like syndrome; elevated serum lactates NDUFS3
Homozygous c.642_644delTGA, 
p.(Asp214del) 26% n.a.
Nuclear-encoded Complex I assembly factors
P9 F Paediatric Leigh-like syndrome; elevated lactates NDUFAF6
Compound heterozygous 
c.805 C > T, p.(His269Tyr) 
and c.581-7 A > G, p.(Leu193_
Gly194insValIle)
26% n.a.
P10 F Paediatric
Lethal infantile mitochondrial 
disease presentation; 
presented day 1 with 
persistent lactic acidosis; died 
at 9 weeks
NDUFAF6 Homozygous c.659 C > A, p.(Thr220Lys) 45% n.a.
P11 F Paediatric
Presented at 8 months; 
developmental regression, 
rotatory nystagmus 
bilaterally; elevated blood 
and CSF lactate; extensive 
basal ganglia and brainstem 
changes on MRI
NDUFAF5
Compound heterozygous 
c.826 C > T, p.(Arg276*) and 
c.848 C > T, p.(Ala283Val)
44% n.a.
P12 M Paediatric Myoclonic seizures, developmental delay FOXRED1
Compound heterozygous 
c.612_615dup, p.(Ala206Serfs*15) 
and c.1261 G > A, p.(Val421Met)
31% n.a.
P13 M Paediatric
Hypertrophic 
cardiomyopathy at birth; 
severe metabolic acidosis 
(18–30 mmol/L); died at 2 
days of age
ACAD9
Compound heterozygous 
c.868 G > A, p.(Gly290Arg) and 
c.976 G > C, p.(Ala326Pro)
13% n.a.
P14 M Adult
Exercise intolerance, muscle 
cramps, elevated serum 
lactate
ACAD9
Compound heterozygous 
c.1150 G > A, p.(Val384Met) and 
c.1168 G > A, p.(Ala390Thr)
13% n.a.
P15d M Adult
Exercise intolerance, unable 
to perform sustained 
aerobic exercise; normal 
strength; normal ECG and 
echocardiogram; normal 
resting lactate, normal CK
TMEM126B Homozygous c.635 G > T, p.(Gly212Val) 36% n.a.
Mitochondrial DNA-encoded Complex I structural subunits
P16e F Adult Exercise intolerance, persistent lactic acidaemia MTND1 m.3356 T > C, p.(Met17Thr) 3% 92%
P17 M Paediatric Leigh syndrome MTND3 m.10158 T > C, p.(Ser34Pro) 44% 90%
P18 M Paediatric Leigh syndrome MTND3 m.10197 G > A, p.(Ala47Thr) n.d. 93%
P19 M Paediatric Leigh syndrome MTND5 m.13514 A > G, p.(Asp393Gly) 27% 66%
P20f F Paediatric
Chronic renal failure, 
myopathy and persistent 
lactic acidosis
MTND5 m.12425delA, p.(Asn30Thrfs*7) 16% 85%
P21 F Paediatric
Bilateral ptosis, 
ophthalmoplegia, pyramidal 
tract signs, elevated blood and 
CSF lactates
MTND5 m.13094 T > C, p.(Val253Ala) 59% 58%
Continued
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 15676  | DOI:10.1038/s41598-017-14623-2
Group 2: Nuclear-encoded CI assembly factors. Similar to patients in Group 1, all seven patients with 
pathogenic variants in nuclear-encoded assembly factors (Group 2), displayed a severe loss of NDUFB8 subu-
nit immunoreactivity (Supplementary Fig. S2). With the exception of P11, further quantification showed that 
the percentage of CI-deficient fibres was > 96%, highlighting the severe loss of NDUFB8. Specifically, the assay 
detected a complete loss of NDUFB8 immunoreactivity (100% CI-deficient fibres) in patients P13, P14 and P15 
all of whom had pathogenic variants in either the ACAD9 or TMEM126B genes; these encode CI assembly factors 
involved in the biogenesis of the proximal part of the P module (PP). Only P11, who has compound heterozygous 
pathogenic variants in the NDUFAF5 gene, encoding a CI assembly factor involved in an early step of the biogen-
esis of the holoenzyme, maintained a relatively normal level of NDUFB8 (26% CI-deficient fibres). As previously 
observed in patients from Group 1, the mitochondrial respiratory chain profiles from patients in Group 2 (Fig. 2) 
similarly showed a “shifting to the left”, but to a greater extent. Again, the IHC findings correlated with available 
biochemical results which show a more severe decrease in muscle CI activity (Table 1).
Patient Gender Adult/Paediatric Clinical Presentation Gene Genetic Defect
Residual Complex 
I activity
Mutation 
Load
P22 M Adult Mitochondrial myopathy, elevated lactates MTND5 m.13513 G > A, p.(Asp393Asn) 39% 60%
P23 M Paediatric Leigh syndrome MTND5 m.13513 G > A, p.(Asp393Asn) 38% 77%
P24 F Adult Elevated CK, muscle pain and fatigue, myopathy MTND5 m.13513 G > A, p.(Asp393Asn) 100% 45%
P25 M Paediatric
Failure to strive, myopathy, 
increased brainstem signal on 
MRI, lactic acidosis
MTND5 m.13513 G > A, p.(Asp393Asn) 100% 63%
Table 1. Clinical, biochemical and molecular genetic characteristics of our patient cohort with isolated 
Complex I deficiency. Residual Complex I activities, normalised to the activity of the matrix marker enzyme 
citrate synthase, are expresses as a percentage of mean control values. Residual Complex I activity and 
mtDNA mutation load measured in muscle. Key: IUGR, intrauterine growth restriction; FTT, failure to 
thrive; ECG, electrocardiogram; CK, creatinine kinase; a,b,c,d,epublished patients: aP1 = Patient 3 in Alston 
et al.16, bP2 = Patient 2 in Alston et al.16, cP3 = Patient 6 in Alston et al.16, dP15 = Patient S1 in Alston et al.20, 
eP16 = Patient 1 in Gorman et al.27, eP20 = Patient published in Alston et al.26, F; Female, M; Male, n.a.; not 
applicable, n.d.; not determined.
Patient ID
IHC findings - % of 
CI deficient fibres
Total number of 
fibres analysed
Nuclear-encoded Complex I 
structural subunits
P1 79% 4372
P2 93% 559
P3 39% 13422
P4 98% 5964
P5 89% 4683
P6 79% 880
P7 99% 5337
P8 96% 7154
Nuclear-encoded Complex I 
assembly factors
P9 99% 9504
P10 96% 5355
P11 26% 7352
P12 96% 1708
P13 100% 2684
P14 100% 239
P15 100% 131
Mitochondrial DNA-
encoded Complex I 
structural core subunits
P16 92% 696
P17 90% 5842
P18 0% 7302
P19 0% 2427
P20 100% 3795
P21 0% 1311
P22 0% 3341
P23 0% 2730
P24 0% 675
P25 0% 785
Table 2. Percentage of Complex I (CI) deficient fibres detected with the IHC assay.
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Figure 1. Mitochondrial respiratory chain expression profile linking complex I, complex IV and porin levels in 
patients with isolated Complex I deficiency caused by defects in nuclear-encoded Complex I subunits. Graphs 
show complex I and complex IV expression profile from (A) Normal adult control and patients with (B–D) 
homozygous c.64T>C, p.(Trp22Arg) NDUFB3 variant, P1–n = 4372 fibres analysed, P2–n = 559, P3–n = 13422 
(E) compound heterozygous NDUFS4 variant, P4, n = 5964 (F) Homozygous exon 3 and 4 deletion in NDUFS4, 
P5, n = 4683 (G) homozygous NDUFS6 variant, P6, n = 880 (H) Homozygous NDUFS2 variant, P7, n = 5337 
(I) Homozygous NDUFS3 variant, P8, n = 7154. Each dot represents a single muscle fibre, colour co-ordinated 
according to its mitochondrial mass: very low – blue, low – light blue, normal – beige, high – orange, very high 
- red. Black dashed lines represent the SD limits for the classification of the fibres. Lines adjacent to X and Y 
axis represent the levels of NDUFB8 and COX-1: beige: normal (<−3), light beige: intermediate (+) (−3 to 
−4.5), light blue: intermediate (−) (−4.5 to −6) and blue: deficient (>−6). Bold dashed lines indicate the mean 
expression level of normal fibres.
www.nature.com/scientificreports/
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IHC shows variable results in patients with mutations in mtDNA-encoded CI subunits (Group 3). 
Patients harbouring mutations in mtDNA genes encoding core structural subunits of Complex I (Group 3, 
n = 10) showed more heterogeneous results. The IHC assay detected 100% CI-deficient fibres, representing a 
complete loss of NDUFB8 immunoreactivity, in three previously-reported patients with high levels of pathogenic 
mtDNA variants in muscle; P16 who has a m.3356 T > C, p.(Met17Thr) MTND1 variant, P17 who harbours a 
m.10158 T > C, p.(Ser34Pro) MTND3 variant and P20 who harbours a m.12425delA MTND5 frameshift muta-
tion (see Supplementary Fig. S3 and Table 2). As expected, the mitochondrial respiratory chain profiles for these 
three patients were all shifted to the left, consistent with the loss of NDUFB8 immunoreactivity associated with 
preserved COX-I immunoreactivity (Fig. 3).
The remaining 7 patients (P18, P19, P21, P22, P23, P24 and P25) showed NDUFB8 immunoreactivity similar 
to control muscle (Supplementary Fig. S4 and Table 2). The mitochondrial respiratory chain profiles demonstrated 
normal respiratory chain function as all fibres fell within the normal range (with Z scores between -3SD and 3 SD) 
(Fig. 3). Of these 7 patients, P22- P25 all harbour a common pathogenic m.13513 G > A, p.(Asp393Asn) MTND5 
variant, P19 harbours a m.13514 A > G, p.(Asp393Gly) variant, P21 harbours a m.13094 T > C, p.(Val253Ala) 
variant whilst P18 has high levels of a m.10197 G > A, p.(Ala393Thr) MTND3 variant. Detection of normal levels 
of immunoreactive NDUFB8 subunit in these patients could be due to these variants only affecting the catalytic 
function of CI rather than the assembly of the enzyme complex.
Patients with mutations in mtDNA-encoded CI subunits and normal NDUFB8 profile also dis-
play normal NDUFS3 levels. Since interrogation of NDUFB8 immunoreactivity failed to detect CI defi-
ciency in 7 of the 10 patients with mtDNA-encoded structural CI mutations, we further investigated whether any 
deficiency could be detected using an alternative, but commercially-available CI antibody targeting NDUFS3 – a 
subunit which is integrated during the early stage of complex I assembly. The IHC assay was performed on 10μm 
muscle sections from P18, P19, P20, P21, P23, P4 and P25 using antibodies against NDUFS3, porin, COX-I and 
laminin, and showed normal NDUFS3 immunoreactivity (Supplementary Fig. S5). As shown in Fig. 4, the mito-
chondrial respiratory chain profile for P20 shows a shift of fibres to the left whilst for all the remaining patients 
also tested with NDUFS3 fall into the normal range – these findings are the same as the assessment with the 
NDUFB8 antibody
BN-PAGE assessing the steady-state levels of fully-assembled Complex I. To further interrogate 
the IHC results observed in the subset of patients displaying normal NDUFB8 and NDUFS3 immunoreactivity, 
we performed BN-PAGE analysis to assess the steady-state levels of fully assembled CI (980 kDa) where muscle 
was available (P18, P19, P21, P22, P23 and P25). P17 was also included as a positive control in this analysis given 
the IHC assay had shown down-regulated levels of NDUFB8 immunoreactivity. Samples prepared for BN-PAGE 
analysis retain OXPHOS complexes in their structural and active form, permitting the investigation of any effects 
on the assembly of the holoenzyme or catalytic activity. Since we had previously measured residual CI activity 
spectrophotometrically, we only assessed the levels of fully assembled complex I, using complex II assembly as a 
control.
Analysis of muscle mitochondrial fractions by BN-PAGE revealed a decrease in steady-state levels of 
fully-assembled CI in P17, P18, P23 and, P24 (Fig. 5) when compared to controls, indicating that the mutations 
harboured by these patients affect levels of fully-assembled CI. As complex II activity is normal in these patients, 
we targeted SDHA subunit and used the steady-state levels of assembled complex II (detected by immunoreactiv-
ity against the SDHA subunit) as a loading control. By contrast, patients P19, P21 and P22 showed normal levels 
of fully assembled CI, in line with the IHC assay results, therefore likely indicating that these mutations affect the 
activity of the complex rather than CI assembly.
The level of CI was also normal in P25, correlating with the findings from the IHC (Fig. 5). Furthermore, the 
residual biochemical CI activity was also 100%, indicative that the m.13513 G > A, p.(Asp393Asn) variant in this 
case has no major effect on the activity or assembly of CI despite the relatively high level of mtDNA heteroplasmy 
(Table 1).
Discussion
This study aimed to assess and validate the application of a recently developed quadruple immunofluorescent 
OXPHOS assay to the diagnosis of patients with isolated mitochondrial CI deficiency. The IHC assay, which 
detects NDUFB8 as a marker of CI integrity, was successful in detecting CI deficiency in 18 of the 25 patients 
tested, including all patients with pathogenic variants in nuclear genes encoding CI structural subunits and 
assembly factors. However, only 3 of the 10 patients harbouring pathogenic mtDNA variants showed a con-
sistent decrease in NDUFB8 immunoreactivity and thus protein abundance, later confirmed using a further 
commercially-available antibody against NDUFS3, another key component of CI. We chose to optimise the IHC 
assay using a commercially-available and widely-used antibody against NDUFB8. The subunit is assembled at the 
mid/late stage of assembly, alongside the mtDNA-encoded core structural subunit, ND5. Although, it would have 
been preferable to use an antibody targeting a mtDNA-encoded subunit, such as ND1 (interrogating the early 
stage of CI assembly), there are currently no robust, commercially-available antibodies raised against this or other 
mtDNA subunits, important to consider if the assay is to be adopted across diagnostic centres.
Using this assay, we could detect CI deficiency in patients that harboured mutations in nuclear genes encoding 
either the accessory, (P1, P2, P3 = NDUFB3 subunit of the P-D region of the P-module, P4 and P5 = NDUFS4 
subunit of the N-module, P6 = NDUFS6 subunit of the N-Module, P7 = NDUFS2 subunit of the Q-module) or 
core subunits (P8 = NDUFS3 subunit of the Q-module) of CI, in line with the biochemical findings. Of inter-
est, we note that despite patients 1, 2 and 3 harbouring the same genetic variant (p.Trp22Arg in NDUFB3) and 
similar residual CI activities, the IHC findings showed variable levels of NDUBF8 immunoreactivity (P1 = 79%, 
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Figure 2. Mitochondrial respiratory chain expression profile linking complex I, complex IV and porin levels in 
patients with isolated Complex I deficiency caused by defects in nuclear-encoded Complex I assembly factors. 
Graphs show complex I and complex IV expression profile from patients with (A) Compound heterozygous 
NDUFAF6 variant, P9, n = 9504 fibres analysed (B) Homozygous NDUFAF6 variant, P10, n = 5355 (C) 
Compound heterozygous NDUFAF5 variant, P11, n = 7352 (D) Compound heterozygous FOXRED1 variant, 
P12, n = 1708 (E–F) Compound heterozygous ACAD9 variant, (E = P13, n = 2684, F = P14, n = 239) (G) 
Homozygous TMEM126B variant, P15, n = 131. Each dot represents a single muscle fibre, colour co-ordinated 
according to its mitochondrial mass: very low – blue, low - light blue, normal – beige, high – orange, very high -  
red. Black dashed lines represent the SD limits for the classification of the fibres. Lines adjacent to X and Y axis 
represent the levels of NDUFB8 and COX-1: beige: normal (<−3), light beige: intermediate (+) (−3 to −4.5),  
light blue: intermediate (−) (−4.5 to −6) and blue: deficient (>−6). Bold dashed lines indicate the mean 
expression level of normal fibres.
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Figure 3. Mitochondrial respiratory chain expression profile linking complex I (NDUFB8), complex 
IV and porin levels in patients with isolated Complex I deficiency caused by defects in mtDNA-encoded 
Complex I subunits. Graphs show complex I and complex IV expression profile from patients with (A) 
m.3356T>C MTND1 variant, P16, n = 696 fibres analysed (B) m.10158T>C MTND3 variant, P17, n = 5842 
(C) m.10197G>A MTND3 variant, P18, n = 7302 (D) m.13514A>G MTND5 variant, P19, n = 2427 
(E) m.12425delA MTND5 variant, P20, n = 3795 (F) m.13094T>C MTND5 variant, P21, n = 1311 (G) 
m.13513G>A MTND5 variant, P22, n = 3341 (H) m.13513G>A MTND5 variant, P23, n = 2730 (I) 
m.13513G>A MTND5 variant, P24, n = 675 (J) m.13513G>A MTND5 variant, P25, n = 785. Each dot 
represents a single muscle fibre, colour co-ordinated according to its mitochondrial mass: very low – blue, low 
- light blue, normal – beige, high – orange, very high - red. Black dashed lines represent the SD limits for the 
classification of the fibres. Lines adjacent to X and Y axis represent the levels of NDUFB8 and COX-1: beige: 
normal (<−3), light beige: intermediate (+) (−3 to −4.5), light blue: intermediate (−) (−4.5 to −6) and blue: 
deficient (>−6). Bold dashed lines indicate the mean expression level of normal fibres.
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Figure 4. Mitochondrial respiratory chain expression profile linking complex I (NDUFS3), complex 
IV and porin levels in patients with Isolated complex I deficiency caused by defects in mtDNA-encoded 
Complex I subunits. Graphs show complex I and complex IV expression profile from patients with (A) 
m.12425delA MTND5 variant, P20, n = 5536 fibres analysed (B) m.10197G>A MTND3 variant, P18, 
n = 6645 (C) m.13514A>G MTND5 variant, P19, n = 2730 (D) m.13094T>C MTND5 variant, P21, n = 3979 
(E) m.13513G>A MTND5 variant, P23, n = 10009 (F) m.13513G>A MTND5 variant, P24, n = 575 (G) 
m.13513G>A MTND5 variant, P25, n = 1168. Each dot represents a single muscle fibre, colour co-ordinated 
according to its mitochondrial mass: very low – blue, low - light blue, normal – beige, high – orange, very high 
- red. Black dashed lines represent the SD limits for the classification of the fibres. Lines adjacent to X and Y 
axis represent the levels of NDUFB8 and COX-1: beige: normal (<−3), light beige: intermediate (+) (−3 to 
−4.5), light blue: intermediate (−) (−4.5 to −6) and blue: deficient (>−6). Bold dashed lines indicate the mean 
expression level of normal fibres.
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P2 = 93% P3 = 39%). However, these findings are consistent with the steady-state levels of the NDUFB8 subunit 
of CI on western and BN-PAGE originally reported by Alston and colleagues, where it was shown that P1 and P2 
(P3 and P2 respectively in ref.16) had decreased protein levels when compared to P3 (P6 in ref.16). Taken together, 
the collective data highlight the potential of the IHC assay to be a diagnostic tool for such cases and shows 
that all mutations in Group 1 exerted a similar effect on steady-state levels of fully assembled CI as previously 
documented16,18,19.
Similarly, the IHC assay was able to diagnose all patients with genetic variants in CI assembly factors. As 
expected, mutation of these genes led to a decrease in CI assembly and accordingly our IHC assay recorded a 
marked loss of CI immunoreactivity in many of the fibres analysed; a complete loss of NDUFB8 immunoreactiv-
ity (100% CI-deficient fibres) was noted in P13, P14 (ACAD9 variants) and P15 (TMEM126B variant), consistent 
with previous reports of severe CI deficiency in ACAD9 and TMEM126B mutations20–23. These two assembly 
factors, alongside with NDUFAF1, ECSIT and TIMMDC1 form the ‘Mitochondrial CI assembly’ (MCIA) com-
plex24 which is associated with the assembly of the P-P submodule (that contains the ND2, ND3, ND4-L and ND6 
mitochondrial- encoded subunits). Since depletion of TMEM126B leads to the accumulation of the Q/PP-a (Q 
module-ND1) intermediate, it seems that NDUFB8 is unstable and as such degraded before the complete assem-
bly of the holoenzyme, explaining why a complete loss of NDUFB8 protein is observed in all fibres24,25.
For patients with pathogenic variants in mtDNA-encoded CI structural subunits, the IHC assay was able 
to detect CI deficiency in 3 patients (P16, P17 and P20). The m.12425delA MTND5 mutation in P20 leads to a 
truncated form of the ND5 subunit which has previously been shown to have a severe impact on CI assembly26. 
This was supported by our IHC results where we observed a complete loss of NDUFB8 immunoreactivity (100% 
CI-deficient fibres). Similarly, P16 harbours a m.3356 T > C, p.(Met17Thr) MTND1 variant at high levels in mus-
cle associated with a severe defect in CI assembly27, corroborating our IHC results ( > 90% CI-deficient fibres). 
Finally, P17 harbours a m.10158 T > C, p.(Ser34Pro) MTND3 variant, leading to a marked decrease in NDUFB8 
immunoreactivity and steady-state levels of fully-assembled CI; together these results show that the IHC assay 
confidently detects the deficiency associated with mtDNA variants which severely impact upon CI assembly.
The remaining 7 patients, where normal NDUFB8 (and, where tested, NDUFS3) immunoreactivity was 
detected, harbour well-characterised pathogenic variants in either the MTND5 (P19, P21, P22, P23, P24 and 
P25) or MTND3 genes (P18). It has been shown that missense variants in these proteins predominantly affect 
CI redox activity whereas mutations in the MTND1, MTND2 and MTND6 genes have a more severe impact on 
complex assembly28–33. We speculate that the patient mutations in which we found normal levels of CI based on 
both IHC and BN-PAGE analysis (P19: MTND5, m.13514 A > G, p.(Asp393Gly); P21: MTND5, m.13094 T > C, 
p.(Val253Thr); P22: MTND5, m.13513 G > A, p.(Asp393Asn)) are likely to only affect the catalytic site of the 
holoenzyme without disturbing CI stability and assembly. In line with this, the m.13514 A > G MTND5 mutation 
(P19) has been shown to affect the redox activity of CI34–36. The change of amino acid at position 393 (which is 
part of a putative quinone-reactive site of the enzyme), causes a loss of the putative quinone-reactive site, thereby 
Figure 5. Analysis of Complex I assembly by BN-PAGE. Complex I assembly profiles were analysed using one 
dimensional blue native polyacrylamide gel electrophoresis (BN-PAGE) (4-16% gradient). Analysis showed a 
decrease in fully-assembled CI in patients P17, P18, P23 and P24, whilst normal assembly is seen in patients 
P19, P21, P22 and P25. Complex II was used a loading control. Both OXPHOS complexes were detected by 
immunoblotting using subunit specific antibodies – NDUFB8 (Complex I) and SDHA (complex II). The 
original, full length blots are included in the Supplementary Information File (Supplementary Fig. S6).
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leading to a decline in CI activity37,38 and validating the IHC findings. Patients harbouring mtDNA variants which 
only affect CI catalytic activity are likely to show normal IHC profiles.
Furthermore, many studies have also shown that defects in the MTND3 and MTND5 genes display variable 
biochemical phenotypes; either decreased redox activities as determined by biochemical spectrophotometric 
assays, decreased levels of fully assembled CI or both18,31,34–36,39–45. This supports the variability found in our 
results as the m.13513 G > A, p.(Asp393Asn) variant, the most frequently occurring mutation in the MTND5 
gene43, can manifest differing effects: either a decrease in fully assembled CI (P23 and P24) or normal levels of 
assembled CI (P25)18,34,35,38–43. Somewhat surprisingly, P25 (mean m.13513 G > A heteroplasmy level of 63% in 
muscle) also presented with normal redox activity and CI assembly profiles, likely due to the confounding factor 
of mutant load. While most pathogenic mtDNA variants cause a biochemical defect only when the levels of muta-
tions mtDNA exceeds 80–90%46, lower thresholds are reported in patients with CI deficiency due to structural 
subunit mutation35,41. In the case of P25, it could be possible that the pathogenic threshold in this patient is higher, 
thereby explaining the absence of a biochemical defect despite the presence of relatively high mutation levels and 
an associated clinical phenotype.
Finally, we detected normal NDUFB8 immunoreactivity but decreased levels of fully-assembled CI in patient 
P18 harbouring a pathogenic m.10197 G > A, p.(Ala47Thr) MTND3 variant. This has previously been associated 
with decreased redox activity and diminished levels of fully-assembled CI31,44,45; unfortunately, due to inadequate 
amounts of skeletal muscle tissue from this patient, we were unable to verify if an effect on activity was also 
present. Our IHC data indicate, however, that the subunit must be present as the NDUFB8 level was normal. 
Interrogating NDUFS3 levels also showed normal results, suggesting that our IHC assay is less able to identify CI 
defects associated with pathogenic variants causing milder defects in CI assembly.
We believe our assay contributes to available diagnostic tools for studying mitochondrial diseases which 
are typified by extensive biochemical, genetic and clinical heterogeneity. Whilst all patients in our cohort with 
Mendelian CI defects showed a decrease or complete loss of NDUFB8 immunoreactivity and redox activity, 
patients with mtDNA variants affecting CI subunits displayed variable biochemical phenotypes. Consequently, we 
emphasise the importance of complete mitochondrial genome sequencing in the diagnostic work up of patients 
with suspected mitochondrial disease, to identify possible pathogenic variants associated with clinical symptoms 
that may result from mutation of mtDNA-encoded structural CI subunits.
In conclusion, our study has accessed and validated the use of a quadruple IHC assay in a diagnostic setting for 
identifying patients with suspected CI deficiency using a single 10 µm transverse skeletal muscle section. We have 
been able to directly detect varying levels of NDUFB8 protein abundance at a single cell level, a key advantage of 
the IHC assay in comparison to current histochemical and histological methodologies. Given these data, we have 
been able to provide evidence that this assay has clear diagnostic potential for patients with CI deficiency, particu-
larly for those with mutations affecting nuclear-encoded genes, which account for ~75–80% of genetic causes of 
CI deficiency. Whilst the assay is not sufficiently sensitive to identify a biochemical defect associated with some 
very well-characterised mtDNA – or rare catalytic defects affecting either mtDNA-encoded or nuclear-encoded 
CI subunits – we believe that a combination of the quadruple IHC assay, in tandem with full mitochondrial 
genome sequencing and standard biochemical assays, can be used to investigate likely genetic causes of CI defi-
ciency in patients with mitochondrial disease, especially when muscle biopsy sample sizes are small necessitating 
the analysis of cryosectioned material.
Methods
Tissue Samples and patient cohort. 25 skeletal muscle biopsies (quadriceps muscle) of patients -both 
paediatrics (<16 years of age) and adults (>16 years of age), who have been investigated for mitochondrial 
disease and shown to have genetically-confirmed pathogenic variants attributed to isolated CI deficiency were 
included in this study (see Table 1 for detailed information). Measurements of the enzymatic activities of respira-
tory chain complexes were undertaken at one of two Mitochondrial Diagnostic laboratories, the NHS Highly 
Specialised Services located within the Wellcome Centre for Mitochondrial Research at Newcastle University or 
the Neurometabolic Laboratory at University College London Hospitals (UCLH). Muscle biopsy referral, enzyme 
measurements and genetic studies were all undertaken as part of the diagnostic work-up of these patients for 
suspected mitochondrial disease. All samples were obtained and used with informed consent. This study was 
approved and performed under the ethical guidelines issued by the Newcastle and North Tyneside Local Research 
Ethics Committees (reference 09/H0906/75) and complied with the Declaration of Helsinki. Control muscle was 
obtained from patients who were undergoing anterior cruciate ligament (ACL) operations and shown to have 
normal respiratory enzyme activities.
Quadruple Immunohistochemistry. Quadruple immunohistochemistry was undertaken on 10 µm sec-
tions as described by Rocha et al.17. Briefly, sections were incubated with the primary antibodies (Supplementary 
Table S1) overnight at 4 °C followed by a three wash steps for 10 minutes. This was followed by incubation with 
secondary antibodies for 2 hours in 4 °C and a further incubation step with streptavidin conjugated with Alexa 
647 for 2 hours at 4 °C (Supplementary Table S1). Sections were then mounted using ProLong gold antifade rea-
gent. No-primary antibody control (NPC) sections (incubated only with the anti-laminin primary antibody), 
were processed alongside each muscle sample.
Image Acquisition. Tiled fluorescent images were taken at x20 magnification using a Zen 2011 (blue edi-
tion) software and Zeiss Axio imager MI microscope, equipped with a motorised stage, an AxioCam digital cam-
era and filter cubes detecting wavelengths at 488 nm, 546 nm, 647 nm and 750 nm. Exposure times were set for 
each channel to avoid over saturation – the same exposure times were then maintained across all cases.
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Statistical Analysis. Densitometry measurements. Fluorescent images were analysed using an in-house 
analysis software coded for by MatLab 2015a. The laminin immunofluorescence (750 channel) was used to detect 
fibres automatically. Any unwanted surfaces including those over background, fibres with poor morphology or 
folded were removed. The surfaces allowed for the measurement of mean intensity/optical density (OD) of 488 
(COX-1), 546 (Porin) and 647 (NDUFB8) in each individual fibre. The same procedure was repeated for each 
NPC in order to determine the levels of non-specific binding
Data Analysis. Following image analysis, excel files containing the mean ODs for each case were analysed using 
an in-house web-based tool as previously described14, along with the statistical calculations within the manuscript 
Rocha and colleagues17. This analysis determined the Z scores for porin, COX-1 and NDUFB8 based on their 
expected levels, which were derived using data obtained from control muscle sections. Fibres were classified based on 
the SD limits into groups of NDUFB8 and COX-1 levels; >−3 = normal, −3 to −4.5 = intermediate positive, −4.5 to 
−6 = intermediate negative and <−6 = deficient/negative. Fibres were also classified into levels of porin according 
to Z scores (Z-score: “very low” (porin_Z < −3 SD), “low” (porin_Z between −3 SD and −2 SD), “normal” (porin_Z 
between −2 SD and +2 SD), “high” (porin_Z between +2 SD and +3 SD) and “very high” (porin_Z above +3 SD)).
Blue Native–Polyacrylamide Gel Electrophoresis (BN-PAGE). Mitochondrial fractions from both 
controls and patient muscle were prepared for Blue Native–Polyacrylamide Gel Electrophoresis (BN-PAGE) as 
previously described in detail by Olahova et al., 2015. The protein concentration of samples was determined using 
the Pierce BCA protein assay kit and absorption spectrophotometry measured at 562 nm. A minimum of 150ug 
of muscle mitochondria extracts were loaded on a native 4–16% BisTris gel (Life technologies) and electropho-
retically separated in first dimension according to the NOVEX NativePAGETM Bis-Tris Gel system instructions 
(2 hours, 250 volts). Proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane (Immobilon-P, 
Millipore Corporation) through wet transfer. Thereafter, the membrane was fixed in 8% acetic acid, washed and 
blocked with 5% milk for 1 hour at room temperature. Membrane was then subjected to standard immunoblot-
ting analysis of OXPHOS complexes using primary and horseradish peroxidise conjugated secondary antibodies 
against NDUFB8 (980 kDa CI holoenzyme) and SDHA (140 kDa) (Supplementary Table S2).
References
 1. Swalwell, H. et al. Respiratory chain complex I deficiency caused by mitochondrial DNA mutations. European Journal of Human 
Genetics. 19, 769–775 (2011).
 2. Zhu, J., Vinothkumar, K. R. & Hirst, J. Structure of mammalian respiratory complex I. Nature. 536, 354–358 (2016).
 3. Mimaki, M., Wang, X., McKenzie, M., Thorburn, D. R. & Ryan, M. T. Understanding mitochondrial complex I assembly in health 
and disease. Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1817, 851–862 (2012).
 4. Sánchez-Caballero, L., Guerrero-Castillo, S. & Nijtmans, L. Unraveling the complexity of mitochondrial complex I assembly: A 
dynamic process. Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1857, 980–990 (2016).
 5. Guerrero-Castillo, S. et al. The Assembly Pathway of Mitochondrial Respiratory Chain Complex I. Cell metabolism. 25, 128–139 (2017).
 6. Stroud, D. A. et al. Accessory subunits are integral for assembly and function of human mitochondrial complex I. Nature. 538, 
123–126 (2016).
 7. Sazanov, L. A. A giant molecular proton pump: structure and mechanism of respiratory complex I. Nat Rev Mol Cell Biol. 16, 
375–388 (2015).
 8. Fassone, E. & Rahman, S. Complex I deficiency: clinical features, biochemistry and molecular genetics. Journal of medical genetics. 49, 
578–590 (2012).
 9. McKenzie, M. & Ryan, M. T. Assembly factors of human mitochondrial complex I and their defects in disease. IUBMB life. 62, 
497–502 (2010).
 10. Lazarou, M., McKenzie, M., Ohtake, A., Thorburn, D. R. & Ryan, M. T. Analysis of the assembly profiles for mitochondrial- and 
nuclear-DNA-encoded subunits into complex I. Molecular and cellular biology. 27, 4228–4237 (2007).
 11. Antonicka, H. et al. Identification and characterization of a common set of complex I assembly intermediates in mitochondria from 
patients with complex I deficiency. The Journal of biological chemistry. 278, 43081–43088 (2003).
 12. Vogel, R. O., Smeitink, J. A. M. & Nijtmans, L. G. J. Human mitochondrial complex I assembly: A dynamic and versatile process. 
Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1767, 1215–1227 (2007).
 13. Leman, G. et al. Assembly defects induce oxidative stress in inherited mitochondrial complex I deficiency. The International Journal 
of Biochemistry & Cell Biology. 65, 91–103 (2015).
 14. Alston, C. L., Rocha, M. C., Lax, N. Z., Turnbull, D. M. & Taylor, R. W. The genetics and pathology of mitochondrial disease. The 
Journal of pathology. 241, 236–250 (2017).
 15. Craven, L., Alston, C. L., Taylor, R. W. & Turnbull, D. M. Recent Advances in Mitochondrial Disease. Annual Review of Genomics 
and Human Genetics. 18, 257–275 (2017).
 16. Alston, C. L. et al. A recurrent mitochondrial p.Trp22Arg NDUFB3 variant causes a distinctive facial appearance, short stature and 
a mild biochemical and clinical phenotype. Journal of medical genetics. 53, 634 (2016).
 17. Rocha, M. C. et al. A novel immunofluorescent assay to investigate oxidative phosphorylation deficiency in mitochondrial 
myopathy: understanding mechanisms and improving diagnosis. Scientific reports. 5, 15037 (2015).
 18. Petruzzella, V. et al. A nonsense mutation in the NDUFS4 gene encoding the 18 kDa (AQDQ) subunit of complex I abolishes 
assembly and activity of the complex in a patient with Leigh-like syndrome. Human molecular genetics. 10, 529–535 (2001).
 19. Kirby, D. M. et al. NDUFS6 mutations are a novel cause of lethal neonatal mitochondrial complex I deficiency. The Journal of clinical 
investigation. 114, 837–845 (2004).
 20. Alston, C. L. et al. Biallelic Mutations in TMEM126B Cause Severe Complex I Deficiency with a Variable Clinical Phenotype. 
American journal of human genetics. 99, 217–227 (2016).
 21. Nouws, J. et al. Acyl-CoA dehydrogenase 9 is required for the biogenesis of oxidative phosphorylation complex I. Cell metabolism. 
12, 283–294 (2010).
 22. Nouws, J., te Brinke, H., Nijtmans, L. G. & Houten, S. M. ACAD9, a complex I assembly factor with a moonlighting function in fatty 
acid oxidation deficiencies. Human molecular genetics. 23, 1311–1319 (2014).
 23. Haack, T. B. et al. Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. Nat Genet. 42, 1131–1134 (2010).
 24. Heide, H. et al. Complexome profiling identifies TMEM126B as a component of the mitochondrial complex I assembly complex. 
Cell metabolism. 16, 538–549 (2012).
 25. Guarani, V. et al. TIMMDC1/C3orf1 functions as a membrane-embedded mitochondrial complex I assembly factor through 
association with the MCIA complex. Molecular and cellular biology. 34, 847–861 (2014).
www.nature.com/scientificreports/
13Scientific RepoRts | 7: 15676  | DOI:10.1038/s41598-017-14623-2
 26. Alston, C. L. et al. A novel mitochondrial MTND5 frameshift mutation causing isolated complex I deficiency, renal failure and 
myopathy. Neuromuscular disorders. 20, 131–135 (2010).
 27. Gorman, G. S. et al. Novel MTND1 mutations cause isolated exercise intolerance, complex I deficiency and increased assembly 
factor expression. Clinical Science (London, England: 1979). 128, 895–904 (2015).
 28. Lazarou, M., Thorburn, D. R., Ryan, M. T. & McKenzie, M. Assembly of mitochondrial complex I and defects in disease. Biochimica 
et biophysica acta. 1793, 78–88 (2009).
 29. Perales-Clemente, E. et al. Five entry points of the mitochondrially encoded subunits in mammalian complex I assembly. Molecular 
and cellular biology. 30, 3038–3047 (2010).
 30. Andrews, B., Carroll, J., Ding, S., Fearnley, I. M. & Walker, J. E. Assembly factors for the membrane arm of human complex I. 
Proceedings of the National Academy of Sciences of the United States of America. 110, 18934–18939 (2013).
 31. Kirby, D. M. et al. Mutations of the mitochondrial ND1 gene as a cause of MELAS. Journal of medical genetics. 41, 784–789 (2004).
 32. Ugalde, C. et al. Impaired complex I assembly in a Leigh syndrome patient with a novel missense mutation in the ND6 gene. Annals 
of neurology. 54, 665–669 (2003).
 33. McFarland, R. et al. De novo mutations in the mitochondrial ND3 gene as a cause of infantile mitochondrial encephalopathy and 
complex I deficiency. Annals of neurology. 55, 58–64 (2004).
 34. Bugiani, M. et al. Clinical and molecular findings in children with complex I deficiency. Biochimica et biophysica acta. 1659, 136–147 (2004).
 35. Corona, P. et al. A novel mtDNA mutation in the ND5 subunit of complex I in two MELAS patients. Annals of neurology. 49, 106–110 (2001).
 36. Lebon, S. et al. Recurrent de novo mitochondrial DNA mutations in respiratory chain deficiency. Journal of medical genetics 40, 
896–899 (2003).
 37. Fisher, N. & Rich, P. R. A motif for quinone binding sites in respiratory and photosynthetic systems. Journal of molecular biology. 
296, 1153–1162 (2000).
 38. Blok, M. J. et al. Mutations in the ND5 subunit of complex I of the mitochondrial DNA are a frequent cause of oxidative 
phosphorylation disease. Journal of medical genetics. 44, e74–e74 (2007).
 39. Chol, M. et al. The mitochondrial DNA G13513A MELAS mutation in the NADH dehydrogenase 5 gene is a frequent cause of 
Leigh-like syndrome with isolated complex I deficiency. Journal of medical genetics. 40, 188–191 (2003).
 40. Hanna, M. G., Nelson, I. P., Morgan-Hughes, J. A. & Wood, N. W. MELAS: a new disease associated mitochondrial DNA mutation 
and evidence for further genetic heterogeneity. Journal of neurology, neurosurgery, and psychiatry. 65, 512–517 (1998).
 41. Kirby, D. M. et al. Low mutant load of mitochondrial DNA G13513A mutation can cause Leigh’s disease. Annals of neurology 54, 
473–478 (2003).
 42. Santorelli, F. M. et al. Identification of a novel mutation in the mtDNA ND5 gene associated with MELAS. Biochemical and 
biophysical research communications. 238, 326–328 (1997).
 43. Shanske, S. et al. The G13513A mutation in the ND5 gene of mitochondrial DNA as a common cause of MELAS or Leigh syndrome: 
evidence from 12 cases. Archives of neurology. 65, 368–372 (2008).
 44. Chae, J. H. et al. A novel ND3 mitochondrial DNA mutation in three Korean children with basal ganglia lesions and complex I 
deficiency. Pediatric research. 61, 622–624 (2007).
 45. Sarzi, E. et al. A novel recurrent mitochondrial DNA mutation in ND3 gene is associated with isolated complex I deficiency causing 
Leigh syndrome and dystonia. American journal of medical genetics. Part A. 143A, 33–41 (2007).
 46. Mariotti, C. et al. Defective respiratory capacity and mitochondrial protein synthesis in transformant cybrids harboring the 
tRNALeu(UUR) mutation associated with maternally inherited myopathy and cardiomyopathy. The Journal of clinical investigation. 93, 
1102–1107 (1994).
Acknowledgements
This work is supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the Medical 
Research Council (MRC) Centre for Translational Research in Neuromuscular Disease, Mitochondrial Disease 
Patient Cohort (UK) (G0800674), the Lily Foundation, the UK NIHR Biomedical Research Centre for Ageing 
and Age-related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust, the MRC/EPSRC 
Molecular Pathology Node and the UK NHS Highly Specialised Service for Rare Mitochondrial Disorders of 
Adults and Children. CLA is supported by a National Institute for Health Research (NIHR) doctoral fellowship 
(NIHR-HCS-D12–03–04).
Author Contributions
S.T.A.: acquisition of data, analysis and interpretation of data, statistical analysis, wrote the first draft of 
the manuscript. C.L.A., L.H., I.P.H., G.F., M.O.: acquisition of data, analysis and interpretation of data. S.H.: 
acquisition of data, analysis and interpretation of data, statistical analysis. R.M.: acquisition of clinical data. 
M.C.R.: critical revision of the manuscript for important intellectual content, statistical analysis, study 
supervision. D.M.T., R.W.T.: study concept and design, critical revision of the manuscript for important 
intellectual content, study supervision and coordination, obtaining funding.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-14623-2.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
